Trials / Terminated
TerminatedNCT01752985
Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease
A Double-Blind, Placebo-Controlled, Randomized, Two-stage, Parallel-Group, Adaptive Design Phase 2a Study to Evaluate the Effects of BMS-813160 in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease (DKD) Who Have Residual Macroalbuminuria Despite Treatment With an Inhibitor of the Renin-Angiotensin System
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 319 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether BMS-813160 will reduce the amount of protein loss in the urine of subjects with type 2 diabetes and diabetic kidney disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-813160 | |
| DRUG | Placebo matching with BMS-813160 |
Timeline
- Start date
- 2013-03-18
- Primary completion
- 2015-06-30
- Completion
- 2015-06-30
- First posted
- 2012-12-19
- Last updated
- 2019-07-30
- Results posted
- 2019-06-25
Locations
62 sites across 4 countries: United States, Canada, Denmark, France
Source: ClinicalTrials.gov record NCT01752985. Inclusion in this directory is not an endorsement.